A preclinical study of an experimental cancer therapy has shown single-agent activity in models of glioblastoma, inducing long-term tumour eradications in a proportion of the treated animals. The results were published on 8 October, 2020 in Science Translational Medicine. The developer is Philogen SpA, a clinical-stage biotechnology company with headquarters in Italy.
